Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...

Learn more about whether Halozyme Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Zai Lab Limited or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Bristol-Myers Squibb's key drugs are losing patent protection, while more recently launched drugs are struggling to meet peak revenue expectations. Learn more about BMY stock here.

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...

Bristol-Myers Squibb shares rallied 5.6% Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment. Analysts said ...

Bristol-Myers Squibb Co. must defend against allegations brought by a trustee for certain Celgene Corp. shareholders who got contingent value rights through its 2019 acquisition. UMB Bank NA, suing as ...

Bristol-Myers Squibb Co., which acquired Celgene Corp., and two former Celgene executives agreed to pay $239 million to end an investor class action alleging they misrepresented the approval prospects ...

Rates of MRD negativity, CR/stringent CR, and 30-month PFS were significantly higher with the carfilzomib-based regimens than with the bortezomib-based regimen. Carfilzomib-based regimens outperformed ...

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial In the POLARIX study (ClinicalTrials.gov ...